US panel to discuss imaging products for Alzheimer’s diagnosis
This article was originally published in Clinica
Executive Summary
The US FDA's peripheral and central nervous system drugs advisory panel will meet on October 23 to discuss the clinical development of radionuclide imaging products for the detection of amyloid to assist in the diagnosis of Alzheimer’s disease. Written submissions can be made to the contact person on or before October 8 2008.